Literature DB >> 15915543

HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.

Markus H Hammer1, Sonja Meyer, Gordon Brestrich, Andreas Moosmann, Florian Kern, Lydia Tesfa, Nina Babel, Alexa Mittenzweig, Cliona M Rooney, Wolfgang Hammerschmidt, Hans-Dieter Volk, Petra Reinke.   

Abstract

Adoptive immunotherapy with antigen-specific T cells has been successfully used to treat certain infectious diseases and cancers. Although more patients may profit from T cell therapy, its more frequent use is restricted by limitations in current T cell generation strategies. The most commonly applied peptide-based approaches rely on the knowledge of relevant epitopes. Therefore, T cells cannot be generated for diseases with unknown epitopes or for patients with unfavorable HLA types. We developed a peptide-based approach for HLA type-independent generation of specific T cells against various proteins. It is based on short-time stimulation with peptide libraries that cover most CD4(+) and CD8(+) T cell epitopes of given proteins. The procedure requires no prior knowledge of epitopes because libraries are synthesized solely on the basis of the protein's amino acid sequence. Stimulation is followed by immunomagnetic selection of activated IFN-gamma-secreting cells and nonspecific expansion. To evaluate the protocol, we generated autologous T cells specific for a well-characterized antigen, the human cytomegalovirus phosphoprotein 65 (pp65). Generated T cell lines consisted of pp65-specific CD4(+) and CD8(+) lymphocytes that displayed antigen-specific killing and proliferation. The protocol combines the biosafety of peptide-based approaches with HLA type independence and may help to advance adoptive immunotherapy in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915543     DOI: 10.1002/eji.200526230

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients.

Authors:  Benjamin J D Weist; Patrizia Wehler; Linda El Ahmad; Michael Schmueck-Henneresse; Jason M Millward; Mikalai Nienen; Avidan U Neumann; Petra Reinke; Nina Babel
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

2.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

3.  Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes.

Authors:  Nina Babel; Gordon Brestrich; Lukasz P Gondek; Arne Sattler; Marcin W Wlodarski; Nina Poliak; Nicole Bethke; Andreas Thiel; Markus H Hammer; Petra Reinke; Jaroslaw P Maciejewski
Journal:  J Am Soc Nephrol       Date:  2008-09-17       Impact factor: 10.121

Review 4.  Polyomavirus-associated nephropathy.

Authors:  Cristina Costa; Rossana Cavallo
Journal:  World J Transplant       Date:  2012-12-24

5.  The role of CD4(+) T cells in BKV-specific T cell immunity.

Authors:  B J D Weist; M Schmueck; H Fuehrer; A Sattler; P Reinke; N Babel
Journal:  Med Microbiol Immunol       Date:  2014-07-23       Impact factor: 3.402

6.  Robust Production of Cytomegalovirus pp65-Specific T Cells Using a Fully Automated IFN-γ Cytokine Capture System.

Authors:  Nayoun Kim; Young-Sun Nam; Keon-Il Im; Jung-Yeon Lim; Young-Woo Jeon; Yunejin Song; Jong Wook Lee; Seok-Goo Cho
Journal:  Transfus Med Hemother       Date:  2017-10-04       Impact factor: 3.747

7.  Conditional immortalization of human B cells by CD40 ligation.

Authors:  Martina Wiesner; Caroline Zentz; Christine Mayr; Rainer Wimmer; Wolfgang Hammerschmidt; Reinhard Zeidler; Andreas Moosmann
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

8.  Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients.

Authors:  Leila Amini; Tino Vollmer; Desiree J Wendering; Anke Jurisch; Sybille Landwehr-Kenzel; Natalie Maureen Otto; Karsten Jürchott; Hans-Dieter Volk; Petra Reinke; Michael Schmueck-Henneresse
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

9.  Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice.

Authors:  Sonja Schötterl; Stephan M Huber; Hans Lentzen; Michel Mittelbronn; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-27       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.